Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-22 4:00 pm Purchase | 13G | Aclaris Therapeutics Inc. ACRS | Rock Springs Capital Management LP | 6,761,861 6.320% | 3,763,366 (+125.51%) | View |
| 2024-11-12 4:50 pm Unchanged | 13G | Xilio Therapeutics Inc. XLO | Rock Springs Capital Management LP | 3,003,259 6.830% | 0 (Unchanged) | View |
| 2024-11-12 4:49 pm Purchase | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | Rock Springs Capital Management LP | 47,670,850 6.200% | 7,751,595 (+19.42%) | View |
| 2024-11-12 4:47 pm Sale | 13G | IMMUNOCORE HLDGS PLC ADS IMCR | Rock Springs Capital Management LP | 0 0.000% | -2,661,507 (Position Closed) | View |
| 2024-05-01 4:11 pm Purchase | 13G | Travere Therapeutics Inc. TVTX | Rock Springs Capital Management LP | 4,411,983 5.790% | 4,411,983 (New Position) | View |
| 2024-04-05 2:51 pm Purchase | 13G | Xilio Therapeutics Inc. XLO | Rock Springs Capital Management LP | 3,003,259 8.710% | 1,562,500 (+108.45%) | View |
| 2024-02-14 2:12 pm Purchase | 13G | Xilio Therapeutics Inc. XLO | Rock Springs Capital Management LP | 1,440,759 5.230% | 1,440,759 (New Position) | View |
| 2024-02-14 2:12 pm Sale | 13G | TEMPEST THERAPEUTICS INC TPST | Rock Springs Capital Management LP | 0 0.000% | -823,654 (Position Closed) | View |
| 2024-02-14 2:11 pm Purchase | 13G | SPRUCE BIOSCIENCES INC. SPRB | Rock Springs Capital Management LP | 2,609,125 6.410% | 986,436 (+60.79%) | View |
| 2024-02-14 2:11 pm Unchanged | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | Rock Springs Capital Management LP | 39,919,255 5.690% | 0 (Unchanged) | View |
| 2024-02-14 2:10 pm Purchase | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | Rock Springs Capital Management LP | 39,919,255 6.380% | 8,694,770 (+27.85%) | View |
| 2024-02-14 2:10 pm Purchase | 13G | INOZYME PHARMA INC INZY | Rock Springs Capital Management LP | 3,681,174 5.960% | 595,147 (+19.29%) | View |
| 2024-02-14 2:09 pm Sale | 13G | IMMUNOCORE HLDGS PLC ADS IMCR | Rock Springs Capital Management LP | 2,661,507 5.380% | -659,559 (-19.86%) | View |
| 2024-02-14 2:08 pm Unchanged | 13G | GAMIDA CELL LTD GMDAQ | Rock Springs Capital Management LP | 0 0.000% | 0 (Unchanged) | View |
| 2024-02-14 2:07 pm Unchanged | 13G | SPYRE THERAPEUTICS, INC SYRE | Rock Springs Capital Management LP | 0 0.000% | 0 (Unchanged) | View |
| 2024-02-14 2:06 pm Sale | 13G | AGIOS PHARMACEUTICALS INC. AGIO | Rock Springs Capital Management LP | 2,152,173 3.850% | -844,419 (-28.18%) | View |
| 2024-02-14 2:06 pm Sale | 13G | Aclaris Therapeutics Inc. ACRS | Rock Springs Capital Management LP | 2,998,495 4.230% | -962,754 (-24.30%) | View |
| 2023-02-14 3:01 pm Sale | 13G | Sierra Oncology Inc. SRRA | Rock Springs Capital Management LP | 0 0.000% | -1,184,793 (Position Closed) | View |
| 2023-02-14 3:01 pm Sale | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Rock Springs Capital Management LP | 0 0.000% | -2,581,299 (Position Closed) | View |
| 2023-02-14 3:00 pm Purchase | 13G | MIRUM PHARMACEUTICALS INC MIRM | Rock Springs Capital Management LP | 1,795,733 4.870% | 256,919 (+16.70%) | View |